Insulin Makers and Pharmacy Benefit Managers Face Allegations of Deceptive Pricing in Lawsuit by Health Benefits Fund

The International Union of Operating Engineers Local No. 478 Health Benefits Fund has recently filed a complaint in the US District Court for the District of Connecticut against major insulin manufacturers and pharmacy benefit managers, accusing them of participating in a deceptive pricing scheme. The allegation is that this scheme led to the fund overpaying for diabetes medications.

According to the complaint, Eli Lilly and Co., Novo Nordisk Inc., Sanofi-Aventis U.S. LLC, CVS Caremark, Express Scripts, and OptumRx collaborated to artificially inflate the list prices of insulin. This pricing manipulation allegedly caused the health benefits fund to pay more than necessary for these crucial medications.

The lawsuit suggests that the pharmacy benefit managers and insulin manufacturers engaged in deceptive tactics to maximize profits at the expense of patients and health insurance providers. The plaintiffs argue that these actions violated antitrust laws and were detrimental to those who rely on insulin to manage their diabetes.

The International Union of Operating Engineers Local No. 478 Health Benefits Fund is seeking damages and restitution for the overpayment caused by this alleged pricing scheme, believing it was unfair pricing practices.

In summary, a recent lawsuit filed by the International Union of Operating Engineers Local No. 478 Health Benefits Fund accuses major insulin manufacturers and pharmacy benefit managers of participating in a deceptive pricing scheme that led to overpayment for diabetes medications. The plaintiffs seek damages and restitution for what they believe was unfair pricing practices, arguing that these actions violated antitrust laws and were detrimental to patients who rely on insulin to manage their diabetes.